Autolus To Assess Feasibility Of Cellares' Cell Shuttle Platform To Complement Its Commercial Manufacturing Operations At Nucleus Facility In Stevenage, UK

Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, and Cellares Corp, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Autolus will assess the feasibility of Cellares' Cell Shuttle platform to complement its commercial manufacturing operations at the Nucleus facility in Stevenage, UK.

Autolus commercializes AUCATZYL® (obecabtagene autoleucel; obe-cel), an autologous CD19 CAR T cell therapy approved in the United States, UK, and Europe for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). Obe-cel is also being studied in ongoing clinical trials to potentially expand its use in pediatric r/r B-ALL, and autoimmune diseases, such as lupus and multiple sclerosis.